Does the media refer more to NKTX or AMPH?

In the previous week, Nkarta had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Nkarta's score of 0.59 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ESPR or NKTX?

In the previous week, Nkarta had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Esperion Therapeutics. Nkarta's average media sentiment score of 0.59 beat Esperion Therapeutics' score of 0.51 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CYRX or NKTX?

CryoPort has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $182.94M 4.33 $78.30M $1.35 11.64 Nkarta N/A N/A -$104.08M -$1.34 N/A

Is CYRX or NKTX more profitable?

CryoPort has a net margin of 41.57% compared to Nkarta's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Nkarta N/A -30.90% -24.20%

Does the media prefer CYRX or NKTX?

In the previous week, Nkarta had 1 more articles in the media than CryoPort. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.84 beat Nkarta's score of 0.59 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CLYM or NKTX?

Climb Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is CLYM or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Nkarta N/A -30.90% -24.20%

Does the media prefer CLYM or NKTX?

In the previous week, Nkarta had 1 more articles in the media than Climb Bio. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Climb Bio. Nkarta's average media sentiment score of 0.59 beat Climb Bio's score of 0.37 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, OCS or NKTX?

Nkarta has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 469.04 -$119.44M -$2.13 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is OCS or NKTX more profitable?

Nkarta has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Nkarta's return on equity of -30.90% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Nkarta N/A -30.90% -24.20%

Does the media refer more to OCS or NKTX?

In the previous week, Nkarta had 2 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Nkarta and 1 mentions for Oculis. Nkarta's average media sentiment score of 0.59 beat Oculis' score of 0.00 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nkarta (NKTX) Competitors

$2.57 -0.03 (-1.15%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$2.60 +0.03 (+1.01%)

As of 07:35 AM Eastern

Compare

NKTX vs. AMPH, ESPR, CYRX, CLYM, and OCS

Should you buy Nkarta stock or one of its competitors? MarketBeat compares Nkarta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nkarta include Amphastar Pharmaceuticals (AMPH), Esperion Therapeutics (ESPR), CryoPort (CYRX), Climb Bio (CLYM), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

How does Nkarta compare to Amphastar Pharmaceuticals?

Nkarta (NASDAQ:NKTX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Nkarta had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Nkarta's score of 0.59 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Nkarta's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

80.5% of Nkarta shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amphastar Pharmaceuticals has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Amphastar Pharmaceuticals	$719.89M	1.20	$98.09M	$1.66	11.83

Nkarta has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Nkarta currently has a consensus price target of $10.75, suggesting a potential upside of 318.29%. Amphastar Pharmaceuticals has a consensus price target of $22.00, suggesting a potential upside of 12.07%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63

Summary

Amphastar Pharmaceuticals beats Nkarta on 9 of the 16 factors compared between the two stocks.

How does Nkarta compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Esperion Therapeutics has a net margin of 0.12% compared to Nkarta's net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Nkarta	N/A	-30.90%	-24.20%

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 74.21%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 318.29%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Esperion Therapeutics has higher revenue and earnings than Nkarta. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nkarta had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Esperion Therapeutics. Nkarta's average media sentiment score of 0.59 beat Esperion Therapeutics' score of 0.51 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Summary

Nkarta beats Esperion Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nkarta compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Nkarta (NASDAQ:NKTX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

CryoPort has a net margin of 41.57% compared to Nkarta's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Nkarta	N/A	-30.90%	-24.20%

CryoPort currently has a consensus target price of $15.11, suggesting a potential downside of 3.81%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 318.29%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CryoPort has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

CryoPort has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$182.94M	4.33	$78.30M	$1.35	11.64
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nkarta had 1 more articles in the media than CryoPort. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.84 beat Nkarta's score of 0.59 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CryoPort beats Nkarta on 11 of the 16 factors compared between the two stocks.

How does Nkarta compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Climb Bio currently has a consensus target price of $21.73, suggesting a potential upside of 77.80%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 318.29%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Nkarta had 1 more articles in the media than Climb Bio. MarketBeat recorded 3 mentions for Nkarta and 2 mentions for Climb Bio. Nkarta's average media sentiment score of 0.59 beat Climb Bio's score of 0.37 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Climb Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Nkarta's return on equity of -30.90% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Nkarta	N/A	-30.90%	-24.20%

Summary

Nkarta beats Climb Bio on 9 of the 14 factors compared between the two stocks.

How does Nkarta compare to Oculis?

Oculis (NASDAQ:OCS) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Nkarta has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	469.04	-$119.44M	-$2.13	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nkarta had 2 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Nkarta and 1 mentions for Oculis. Nkarta's average media sentiment score of 0.59 beat Oculis' score of 0.00 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Oculis currently has a consensus price target of $38.33, suggesting a potential upside of 226.80%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 318.29%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Nkarta has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Nkarta's return on equity of -30.90% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Nkarta	N/A	-30.90%	-24.20%

22.3% of Oculis shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Nkarta beats Oculis on 14 of the 16 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$186.02M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.92	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.05	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.58	7.92	10.62	6.14
Net Income	-$104.08M	$23.81M	$3.60B	$331.74M
7 Day Performance	-3.02%	-1.09%	-1.26%	-1.82%
1 Month Performance	-10.14%	2.56%	1.07%	-1.45%
1 Year Performance	33.85%	42.16%	23.63%	16.32%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	3.7313 of 5 stars	$2.57 -1.2%	$10.75 +318.3%	+34.6%	$186.02M	N/A	N/A	140	Gap Down
AMPH Amphastar Pharmaceuticals	3.2197 of 5 stars	$19.29 +3.0%	$22.00 +14.0%	-4.8%	$825.42M	$719.89M	11.62	1,976
ESPR Esperion Therapeutics	2.8874 of 5 stars	$3.19 +0.3%	$5.54 +73.6%	N/A	$819.47M	$403.14M	N/A	200	High Trading Volume
CYRX CryoPort	3.1316 of 5 stars	$15.71 -2.8%	$15.11 -3.8%	+118.5%	$815.01M	$176.18M	11.64	1,186	News Coverage Positive News
CLYM Climb Bio	2.9542 of 5 stars	$13.21 -5.6%	$21.73 +64.5%	+709.3%	$801.68M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. AMPH, ESPR, CYRX, CLYM, and OCS

How does Nkarta compare to Amphastar Pharmaceuticals?

Summary

How does Nkarta compare to Esperion Therapeutics?

Summary

How does Nkarta compare to CryoPort?

Summary

How does Nkarta compare to Climb Bio?

Summary

How does Nkarta compare to Oculis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. AMPH, ESPR, CYRX, CLYM, and OCS

How does Nkarta compare to Amphastar Pharmaceuticals?

Does the media refer more to NKTX or AMPH?

Is NKTX or AMPH more profitable?

Do insiders & institutionals have more ownership in NKTX or AMPH?

Which has preferable valuation & earnings, NKTX or AMPH?

Which has more risk and volatility, NKTX or AMPH?

Do analysts recommend NKTX or AMPH?

Summary

How does Nkarta compare to Esperion Therapeutics?

Is ESPR or NKTX more profitable?

Do analysts recommend ESPR or NKTX?

Do institutionals & insiders believe in ESPR or NKTX?

Which has better earnings & valuation, ESPR or NKTX?

Does the media prefer ESPR or NKTX?

Which has more volatility & risk, ESPR or NKTX?

Summary

How does Nkarta compare to CryoPort?

Is CYRX or NKTX more profitable?

Do analysts rate CYRX or NKTX?

Do institutionals and insiders have more ownership in CYRX or NKTX?

Which has more volatility & risk, CYRX or NKTX?

Which has better earnings and valuation, CYRX or NKTX?

Does the media prefer CYRX or NKTX?

Summary

How does Nkarta compare to Climb Bio?

Do insiders & institutionals hold more shares of CLYM or NKTX?

Do analysts prefer CLYM or NKTX?

Does the media prefer CLYM or NKTX?

Which has more volatility & risk, CLYM or NKTX?

Which has higher valuation and earnings, CLYM or NKTX?

Is CLYM or NKTX more profitable?

Summary

How does Nkarta compare to Oculis?

Which has higher earnings & valuation, OCS or NKTX?

Does the media refer more to OCS or NKTX?

Which has more risk & volatility, OCS or NKTX?

Do analysts rate OCS or NKTX?

Is OCS or NKTX more profitable?

Do insiders & institutionals hold more shares of OCS or NKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools